Skip to main content
. 2019 Oct 17;11(10):1581. doi: 10.3390/cancers11101581

Figure 2.

Figure 2

Benefits of AZD8055 and AZD2014 over rapamycin to inhibit PI3K/Akt/mTOR pathway. (a) Effects of treatment on phosphorylation of two main mTORC1 (S6RP and 4EBP1) and mTORC2 (AKT) targets, and of ERK after 24 hours treatment. WB are representative of 3 independent experiments. Ctrl: untreated cells; R50: rapamycin at 50 nM; A50: AZD8055 at 50 nM; A200: AZD2014 at 200 nM. (b) Analysis of ERK and AKT phosphorylation after 24h treatment with rapamycin (50 nM), LY294002 PI3K inhibitor (20 μM), or combination of both drugs in SW480 cells. Numbers represent quantification of the density ratio between phosphorylated and either non-phosphorylated form or actin, and normalized to the untreated cells.